Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2022

View Archived Issues

BBT-207, a fourth-generation EGFR TKI with activity against most common mutants

Bristol Myers Squibb describes new FPR1/2 agonists

New KCNA3 channel blockers identified at DE Shaw Research

Vertex Pharmaceuticals discovers CFTR modulators

Curome Biosciences presents new quinone derivatives

New mucolipin-1 activators identified at Lysoway Therapeutics

Innate immune memory underlies inflammatory comorbidities: study

CF-370 shows synergy with amikacin in drug-resistant P. aeruginosa acute pneumonia model

BioNova Pharmaceuticals menin inhibitor BNM-1192 shows promise for MLL rearranged leukemias

Bridge Biotherapeutics and Cyrus Therapeutics generate next-generation EGFR degraders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...